Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Adolfo Aleman, Rongbao Zhao, Leah Grossman, Rahul Sanawar, Srinivas Aluri, Mani Mohindru, Rudra Prasad Dutta, Sidorela Reci, Junia Vieira, David Melnekoff, Alessandro Lagana, Shriya Desai, Sundar Jagannath, Amit Verma, Samir Parekh

Blood (2024) 144 (Supplement 1): 589.

https://doi.org/10.1182/blood-2024-201194

Published: 2024

Journal Articles

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

Tony A. Navas, Mani Mohindru, Myka Estes, Jing Ying Ma, Lubomir Sokol, Perry Pahanish, Simrit Parmar, Edwin Haghnazari, Li Zhou, Robert Collins, Irene Kerr, Aaron N. Nguyen, Yin Xu, Leonidas C. Platanias, Alan A. List, Linda S. Higgins, Amit Verma

Blood (2006) 108 (13): 4170–4177.

https://doi.org/10.1182/blood-2006-05-023093

Published: 2006

Journal Articles

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Amit Verma, Tony A. Navas, Jing Ying, Ma, Aaron N. Nguyen, Perry Pahanish, Mahesh Seetharam, Irene Kerr, Robert Collins, Mimi Kim, Mani Mohindru, Linda S. Higgins

Blood (2005) 106 (11): 3448.

https://doi.org/10.1182/blood.V106.11.3448.3448

Published: 2005

Journal Articles

Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes.

Mani Mohindru, Perry Pahanish, Efstratios Katsoulidis, Robert Collins, Thomas Rogers, Tony Navas, Linda Higgins, Leonidas Platanias, Amit Verma

Blood (2004) 104 (11): 470.

https://doi.org/10.1182/blood.V104.11.470.470

Published: 2004

Journal Articles

Myelosuppresive Effects of Interferon [slpha] and Transforming Growth Factor β Can Be Reversed by Novel p38 MAPK Inhibitor SD-282 through Inhibition of Cell Cycle Arrest.

Mani Mohindru, Perry Pahanish, Robert Collins, Tony Navas, Linda Higgins, Amit Verma

Blood (2004) 104 (11): 4229.

https://doi.org/10.1182/blood.V104.11.4229.4229

Published: 2004

NARROW

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes.

Myelosuppresive Effects of Interferon [slpha] and Transforming Growth Factor β Can Be Reversed by Novel p38 MAPK Inhibitor SD-282 through Inhibition of Cell Cycle Arrest.

Email alerts

ASH Publications

American Society of Hematology

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes.

Myelosuppresive Effects of Interferon [slpha] and Transforming Growth Factor β Can Be Reversed by Novel p38 MAPK Inhibitor SD-282 through Inhibition of Cell Cycle Arrest.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only